Loading...
| A04059 | Pages: NA | Aug 2021 | 5097 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Hyperphosphatemia Drugs Market
Request Now !Hyperphosphatemia is a condition which results in an elevated level of phosphate in the blood. This may occur due to excessive phosphate intake, phosphate shift from intracellular to extracellular space, and decreased phosphate excretion. High phosphate levels in blood can be avoided by use of phosphate binders and dietary constraint of phosphates.
Major factors that drive the market growth are growth in prevalence of chronic diseases and growth in geriatric population. However, stringent regulations by the drug-governing bodies such as FDA and rise in side effects of hyperphosphatemia drugs may impede the market growth. Moreover, high potential in untapped economies, such as India, China, South Africa, and Brazil, is expected to create lucrative opportunities for key players.
The global hyperphosphatemia drugs market is segmented based on product, dosage form, and region. Based on product, it is divided into calcium-based, aluminum-based, magnesium-based, and iron-based phosphate binders. Based on dosage form, it is classified into tablets, syrups, and capsules. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major players, such as Amag Pharmaceuticals, Johnson and Johnson, Keryx Biopharmaceuticals, DSM Biotech Pharmacal, Sun Pharm Inc., Zeria Pharmaceutical, Bruno Pharmaceutical Spa, Fermenta Biotech Ltd, Pfizer Inc. and Roche Diagnostics Corporation are also provided in this report.
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 HYPERPHOSPHATEMIA DRUGS MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. CALCIUM-BASED PHOSPHATE BINDERS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. ALUMINUM-BASED PHOSPHATE BINDERS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. MAGNESIUM-BASED PHOSPHATE BINDERS
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. IRON-BASED PHOSPHATE BINDERS
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
CHAPTER 5 HYPERPHOSPHATEMIA DRUGS MARKET, BY DOSAGE FORMS
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. TABLETS
5.2.1. Market size and forecast
5.3. SYRUPS
5.3.1. Market size and forecast
5.4. CAPSULES
5.4.1. Market size and forecast
CHAPTER 6 HYPERPHOSPHATEMIA DRUGS MARKET, BY GEOGRAPHY
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America Hyperphosphatemia Drugs Market by Product
6.2.5. North America Hyperphosphatemia Drugs Market by Dosage Forms
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Spain market size and forecast
6.3.3.5. Rest of Europe market size and forecast
6.3.4. Europe Hyperphosphatemia Drugs Market by Product
6.3.5. Europe Hyperphosphatemia Drugs Market by Dosage Forms
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Hyperphosphatemia Drugs Market by Product
6.4.5. Asia-Pacific Hyperphosphatemia Drugs Market by Dosage Forms
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast
6.5.4. LAMEA Hyperphosphatemia Drugs Market by Product
6.5.5. LAMEA Hyperphosphatemia Drugs Market by Dosage Forms
CHAPTER 7 COMPANY PROFILES
7.1. AMAG PHARMACEUTICALS
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. JOHNSON AND JOHNSON
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. KERYX BIOPHARMACEUTICALS
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. DSM BIOTECH PHARMACAL
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. SUN PHARM INC.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. ZERIA PHARMACEUTICAL
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. BRUNO PHARMACEUTICAL SPA
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. FERMENTA BIOTECH LTD
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. PFIZER INC.
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. Roche Diagnostics Corporation
7.9.4. Operating business segments
7.9.5. Business performance
7.9.6. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
